Stephen Liu, Director of Thoracic Oncology, Head of Developmental Therapeutics and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“Dr. Noemi Reguart discusses PD1/VEGF bispecifics in NSCLC at Rome Lung 2025. Many compounds in development- ivonescimab and BNT-327 furthest along. Encouraging results from HARMONi-2. Will cooperative binding and complex formation lead to better survival? Need to see full results here.”
More posts featuring Stephen Liu.
